| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
| Total operating expenses | 156,834 | 136,637 | 121,872 | 108,748 |
| Income (loss) from operations | 24,021 | 20,160 | -9,658 | -117 |
| Other income | 3,136 | 2,717 | 2,457 | 2,421 |
| Income (loss) before income taxes | 27,157 | 22,877 | -7,201 | 2,304 |
| Provision for income taxes | 8,722 | 5,045 | 5,492 | 6,212 |
| Net income (loss) | 18,435 | 17,832 | -12,693 | -3,908 |
| Unrealized gain (loss) on short-term investments and currency translation adjustments, net of tax | -102 | 112 | 89 | - |
| Total other comprehensive income (loss) | -102 | 112 | 89 | - |
| Total comprehensive income (loss) | 18,333 | 17,944 | -12,604 | - |
| Earnings per share, basic | 0.25 | 0.24 | -0.18 | -0.06 |
| Earnings per share, diluted | 0.23 | 0.23 | -0.18 | -0.06 |
| Weighted average number of shares outstanding, basic | 74,714,846 | 73,438,530 | 71,726,685 | 71,004,640 |
| Weighted average number of shares outstanding, diluted | 80,035,400 | 77,942,082 | 71,726,685 | 71,004,640 |
Kiniksa Pharmaceuticals International, plc (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA)